Intramuscular aripiprazole in the control of agitation

Journal of Psychiatric Practice

Volumn 13, Issue 3, 2007, Pages 159-169

  Currier, Glenn W ^a   Citrome, Leslie L ^b   Zimbroff, Dan L ^c   Oren, Dan ^d   Manos, George ^d   McQuade, Robert ^e   Pikalov, Andrei A ^e   Crandall, David T ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Pacific Clinical Research Medical Group   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Agitation; Bipolar I disorder; Intramuscular (IM) aripiprazole; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; LORAZEPAM; PLACEBO;

ADULT; AGITATION; AGITATION CALMNESS EVALUATION SCALE; AKATHISIA; ARTICLE; BEHAVIOR CONTROL; BIPOLAR I DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; ECG ABNORMALITY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGICAL RATING SCALE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP PATTERN; SOMNOLENCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; ANTIPSYCHOTIC AGENTS; AROUSAL; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HUMANS; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAMUSCULAR; LORAZEPAM; MALE; MIDDLE AGED; MULTICENTER STUDIES; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 34249284473     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000271657.09717.e2     Document Type: Article

References (36)

1. Battaglia J. Pharmacological management of acute agitation. Drugs 2005;65:1207-22.
2. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003;20:339-46.
3. Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs 2002;16:219-28.
4. Currier GW. Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry 2000;61(Suppl 14):21-6.
5. Allen MH, Currier GW, Hughes DH, et al. The expert consensus guideline series: Treatment of behavioral emergencies. Postgrad Med Special Report 2001;May:1-88.
6. Allen MH, Currier GW, Carpenter D, et al. Expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005;11(Suppl 1):1-108.
7. Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003;21:192-8.
8. Currier GW, Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract 2006;12:30-40.
9. Wynaden D, Landsborough I, Chapman R, et al. Establishing best practice guidelines for administration of intramuscular injections in the adult: A systematic review of the literature. Contemp Nurse 2005;20:267-77.
10. Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs 2003;63:493-512.
11. Citrome L. Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Postgrad Med 2002;112:85-8, 94-6.
12. Currier GW, Allen MH, Bunney EB, et al. Intramuscular antipsychotics: Clinical experience review. J Emerg Med 2004;27(Suppl 4):S3-4; quiz S8.
13. Zimbroff D, Oren DA, Marcus R, et al. Management of acute agitation in patients with bipolar disorder: Efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007;27:171-6.
14. Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68:111-9.
15. Andrezina R, Josiassen R, Marcus R, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: A double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006;188:281-92.
16. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
17. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33; quiz 57.
18. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26:494-504.
19. Balasubramaniam M, Fischgrund JS. Two-tailed Fisher's exact test. Cochran-Mantel-Haenzel Spine J 2002;2:158-9.
20. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
21. Abilify® (aripiprazole). Prescribing Information. Tablets manufactured by Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan, or Bristol-Myers Squibb Company, Princeton, NJ 08543. Injection manufactured by Bristol-Myers Squibb Company, and distributed and marketed by Otsuka American Pharmaceutical, Inc, Rockville, MD 20850 USA. Revised October 2006.
22. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. The Cochrane Database of Systemic Reviews 2005;2:CD003729.
23. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-8.
24. Jones B, Taylor CC, Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry 2001;62;(Suppl 2):22-4.
25. Lindborg SR, Beasley CM, Alaka K, et al. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res 2003;119:113-23.
26. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-97.
27. Wagstaff AJ, Easton J, Scott LJ. Intramuscular olanzapine: A review of its use in the management of acute agitation. CNS Drugs 2005;19:147-64.
28. Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: Antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry 2003;48:716-21.
29. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51.
30. Kerwin R. Olanzapine was more effective than lorazepam at 2 hours but not at 24 hours in bipolar mania with acute agitation. Evid Based Ment Health 2002;5:18-19.
31. Brook S. Intramuscular ziprasidone: Moving beyond the conventional in the treatment of acute agitation in schizophrenia. J Clin Psychiatry 2003;64(Suppl 19):13-18.
32. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology 2001;155:128-34.
33. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-8. Erratum in: J Clin Psychiatry. 2001;62:209.
34. Mendelowitz AJ. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry 2004;16:145-54.
35. Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: A naturalistic study. Gen Hosp Psychiatry 2005;27:140-4.
36. Zimbroff DL, Allen MH, Battaglia J, et al. Best clinical practice with ziprasidone IM: Update after 2 years of experience. CNS Spectr 2005;10:1-15.